IPN Ipsen SA

Annual General Meeting of Ipsen S.A. held on 28 May 2024

Annual General Meeting of Ipsen S.A. held on 28 May 2024

  • All the resolutions submitted to the shareholders’ vote have been adopted

PARIS, FRANCE, 28 May 2024 - The Annual General Meeting of Ipsen S.A. (Euronext: IPN; ADR: IPSEY) was held today at the Salons de l'Hôtel des Arts et Métiers, 9 bis, avenue d'Iéna, 75116 Paris (France), under the chairmanship of Mr. Marc de GARIDEL, Chairman of the Board of Directors, and in the presence of the members of the Board of Directors and the Group’s Executive Leadership Team.

The Annual General Meeting approved all of the 17 resolutions submitted by the Board of Directors and in particular the payment of a dividend of €1.20 per share. This dividend will be paid on 3 June 2024, the ex-date being 30 May 2024.

The Meeting also approved the appointment of PricewaterhouseCoopers Audit as statutory auditor in charge of the certification of sustainability information, the renewal of the terms of office of the company BEECH TREE S.A., represented by Mr. Philippe BONHOMME, and of Mrs. Carol XUEREF as directors, for a duration of four years, and also the ratification of the temporary appointment of Mr. Pascal TOUCHON as director, for the remainder of the term of office of his predecessor.

During the Meeting, Mr. Marc de GARIDEL, Chairman of the Board of Directors, commented on the information concerning the governance and the activity of Ipsen's Board of Directors and its committees during FY 2023. Mr. David LOEW, Chief Executive Officer, and Mr. Aymeric Le CHATELIER, Group Chief Financial Officer, focused notably on the Group strategy, the climate commitments, the 2023 financial performance and the financial objectives for the year 2024.

The results of the votes and the webcast of the Annual General Meeting will be available soon on



Attachment



EN
28/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE

Cabometyx® approved in the EU for previously treated advanced neuroend...

Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors Cabometyx® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin analogue-based systemic therapy1,2Approval based on pivotal CABINET Phase III trial which demonstrated a 77% and 62% reduction in the risk of disease progression or death versus placebo in advanced pancreatic and extra-pancreatic neuroendocrine tumors, respectively3,4 PARIS, FRANCE, 24 July...

 PRESS RELEASE

Approbation de Cabometyx® dans l’UE pour les tumeurs neuroendocrines a...

Approbation de Cabometyx® dans l’UE pour les tumeurs neuroendocrines avancées précédemment traitées Cabometyx® est le premier et unique traitement systémique autorisé dans l’Union européenne pour les tumeurs neuroendocrines non résécables ou métastatiques précédemment traitées, indépendamment de la localisation de la tumeur, de sa gravité et de l’administration ou non d’un traitement systémique auparavant, autre qu’un traitement par analogue de la somatostatine1,2.Approbation basée sur l’essai pivotal de Phase III CABINET qui a démontré une réduction de 77 % et 62 % du risque de progression...

 PRESS RELEASE

Ipsen announces changes to its Executive Committee

Ipsen announces changes to its Executive Committee PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee: Mari Scheiffele is appointed to EVP, Chief Product OfficerAndreas Gerber is appointed to EVP, Head of InternationalCaroline Sitbon is appointed to EVP, General Counsel Mari, Andreas and Caroline will report to Ipsen’s Chief Executive Officer, David Loew, beginning September 1, 2025. After 4 years successfully leading the commercial operations for the Internat...

 PRESS RELEASE

Ipsen annonce des changements au sein de son Comité Exécutif

Ipsen annonce des changements au sein de son Comité Exécutif PARIS, FRANCE, 23 juillet 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), groupe biopharmaceutique mondial de spécialité, annonce aujourd'hui les changements suivants au sein de son Comité Exécutif : Mari Scheiffele est nommée Vice-Présidente Exécutive, Directrice des Produits.Andreas Gerber est nommé Vice-Président Exécutif, Directeur International.Caroline Sitbon est nommée Vice-Présidente Exécutive, Directrice Juridique. Mari, Andreas et Caroline reporteront à David Loew, Directeur Général d'Ipsen, à compter du 1er septembre 2025. ...

 PRESS RELEASE

IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2025 Aggregated presentation by day and by market Statement of transactions in own shares from July 14th to July 18th 2025        Name of the issuerIdentity code of the issuer (Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code) IPSEN549300M6SGDPB4Z94P1114/07/2025FR0010259150 240 105,775AQEUIPSEN549300M6SGDPB4Z94P1114/07/2025FR0010259150 706 105,86459CCXEIPSEN549300M6SGDPB4Z94P1114/07/2025FR00...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch